en.Wedoany.com Reported - Brazilian pharmaceutical company Biomm (the only domestic producer of insulin glargine) has released its 2026 performance forecast, expecting earnings before interest, taxes, depreciation, and amortization (Ebitda) to reach between 90 million and 100 million reais, a significant turnaround from a negative 69.3 million reais in 2024.
This guidance, signed by Biomm's Chief Financial Officer and Investor Relations Director Marcelo Sáfadi Álvares, was released in a material fact announcement on the evening of June 9. The growth plan relies on increased capacity at its plant in Nova Lima, Minas Gerais (which began operations in 2024), as well as existing insulin glargine production development partnership (PDP) contracts (with Biomanguinhos and Fiocruz) and human insulin contracts (with the Ezequiel Dias Foundation). The company also plans to expand sales of the Glargilin brand (an injectable drug for treating type 1 and type 2 diabetes) in Brazil's private pharmaceutical market.
If the forecast is realized, Biomm's financial performance would represent a year-over-year increase of approximately 3000%. Fourth-quarter results showed the company's Ebitda at 3.3 million reais, compared to a negative 69.3 million reais in 2024, marking the first time Biomm has ended a fiscal year without a loss. The announcement noted that the forecast reflects management's current expectations, does not constitute, guarantee, or predict results, and is subject to fluctuating factors and conditions beyond the company's control.
The release of the guidance marks a significant shift for Biomm, which had never previously disclosed such information to the market. The release was approved at a board meeting on May 28. Previously, Biomm had drawn market attention due to a banking scandal involving shareholder Daniel Vorcaro. Daniel Vorcaro's bank was liquidated by the Central Bank of Brazil in November 2025, and he held a 25.86% stake in the company through the Cartago investment fund. In April this year, asset manager Alaska purchased a 26.15% stake in the company, acquiring most of the shares held by Banco de Brasília (which originally held Cartago's shares), as well as shares from Cedro Participações (which held a 7.8% stake).
Amid potential changes in shareholder control, Biomm replaced its CEO. Guilherme Maradei took office on January 1 this year, succeeding Heraldo Marchezini, who had held the position since 2013. The company stated that the personnel change had been in the works for some time, with the successor selection process taking at least six months. The company was founded in 2001 by Walfrido dos Mares Guia, who previously served as Brazil's Minister of Tourism and currently holds an 8.24% stake. BTGP Gestão holds 12.2%, TMG/IBR holds 7.25%, and the Brazilian Development Bank (BNDES) holds 5.12% through BNDESPar.
In the first quarter of this year, Biomm's net revenue was 92.4 million reais, a 133.5% increase from 39.6 million reais in the first three months of 2025. Net profit was 9.7 million reais, reversing a loss of 11.7 million reais in the same period last year. Before the scandal broke, Biomm had indicated interest in entering Brazil's weight-loss pen market and signed a contract with India's Biocon in 2024 to license and distribute a similar Ozempic product, which is currently awaiting registration with Brazil's National Health Surveillance Agency (Anvisa). The company's market capitalization is 917 million reais. Year-to-date in 2026, BIOM3 shares on the B3 exchange have depreciated by 5.6%, with a 12-month decline of 25%.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
